DK2753334T3 - Fap-aktiverede proteasomhæmmere til behandling af solide tumorer - Google Patents

Fap-aktiverede proteasomhæmmere til behandling af solide tumorer Download PDF

Info

Publication number
DK2753334T3
DK2753334T3 DK12827686.2T DK12827686T DK2753334T3 DK 2753334 T3 DK2753334 T3 DK 2753334T3 DK 12827686 T DK12827686 T DK 12827686T DK 2753334 T3 DK2753334 T3 DK 2753334T3
Authority
DK
Denmark
Prior art keywords
fap
treatment
solid tumors
proteasome inhibitors
activated proteasome
Prior art date
Application number
DK12827686.2T
Other languages
Danish (da)
English (en)
Inventor
Hung-Sen Lai
Sarah E Poplawski
William W Bachovchin
Original Assignee
Tufts College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tufts College filed Critical Tufts College
Application granted granted Critical
Publication of DK2753334T3 publication Critical patent/DK2753334T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK12827686.2T 2011-08-30 2012-08-30 Fap-aktiverede proteasomhæmmere til behandling af solide tumorer DK2753334T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161528824P 2011-08-30 2011-08-30
PCT/US2012/053140 WO2013033396A2 (en) 2011-08-30 2012-08-30 Fap-activated proteasome inhibitors for treating solid tumors

Publications (1)

Publication Number Publication Date
DK2753334T3 true DK2753334T3 (da) 2022-11-07

Family

ID=47757170

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12827686.2T DK2753334T3 (da) 2011-08-30 2012-08-30 Fap-aktiverede proteasomhæmmere til behandling af solide tumorer

Country Status (14)

Country Link
US (6) US9597410B2 (enExample)
EP (3) EP4706663A3 (enExample)
JP (2) JP6207509B2 (enExample)
CN (2) CN103945856A (enExample)
AU (2) AU2012301810B2 (enExample)
CA (1) CA2846852C (enExample)
DK (1) DK2753334T3 (enExample)
ES (1) ES2929179T3 (enExample)
HR (1) HRP20221320T1 (enExample)
HU (1) HUE060305T2 (enExample)
PL (1) PL2753334T3 (enExample)
PT (1) PT2753334T (enExample)
SI (1) SI2753334T1 (enExample)
WO (1) WO2013033396A2 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4706663A3 (en) * 2011-08-30 2026-05-20 Trustees Of Tufts College FAP-ACTIVATED PROTEASOME INHIBITORS USED TO TREAT SOLID TUMORS
EP2925746A1 (en) * 2012-12-03 2015-10-07 F. Hoffmann-La Roche AG Substituted triazole and imidazole compounds
WO2014200969A2 (en) * 2013-06-10 2014-12-18 Millennium Pharmaceuticals, Inc. Methods of treatment of cancer
WO2015076359A1 (ja) * 2013-11-21 2015-05-28 国立大学法人北海道大学 プロテアソーム阻害性化合物
WO2015192124A1 (en) 2014-06-13 2015-12-17 Trustees Of Tufts College Fap-activated therapeutic agents, and uses related thereto
IL325256A (en) * 2014-06-13 2026-02-01 Bach Biosciences Llc FAP-activated medical materials and related uses
US10973920B2 (en) 2014-06-30 2021-04-13 Glykos Finland Oy Saccharide derivative of a toxic payload and antibody conjugates thereof
WO2016011088A2 (en) * 2014-07-14 2016-01-21 Centrax International, Inc. Epoxyketone compounds for enzyme inhibition
CN104231047B (zh) * 2014-08-22 2017-06-16 亚飞（上海）生物医药科技有限公司 水溶性靶向激活的紫杉醇衍生物及其制备和用途
CN106715457B (zh) 2014-08-22 2021-09-28 亚飞（上海）生物医药科技有限公司 一种肿瘤微环境特异激活的小分子靶向偶联体及其用途
WO2016210054A1 (en) * 2015-06-23 2016-12-29 The Board Of Trustees Of The Leland Stanford Junior University Novel rhodol fluorophores for near-infrared imaging
CN106588965A (zh) 2015-10-15 2017-04-26 北京大学 脲拟肽硼酸化合物及其药物组合物、制备方法和用途
CN105938123B (zh) * 2015-12-18 2018-09-14 重庆两江药物研发中心有限公司 一种卡非佐米中间体中杂质的检测方法
WO2017156071A1 (en) 2016-03-09 2017-09-14 Blade Therapeutics, Inc. Cyclic keto-amide compounds as calpain modulators and methods of production and use thereof
JP7164521B2 (ja) 2016-06-21 2022-11-01 オリオン・オフサルモロジー・エルエルシー 炭素環式プロリンアミド誘導体
JP7179721B2 (ja) 2016-06-21 2022-11-29 オリオン・オフサルモロジー・エルエルシー 複素環式プロリンアミド誘導体
AU2017292646A1 (en) 2016-07-05 2019-02-07 Blade Therapeutics, Inc. Calpain modulators and therapeutic uses thereof
US10934261B2 (en) 2016-09-28 2021-03-02 Blade Therapeutics, Inc. Calpain modulators and therapeutic uses thereof
JP7162592B2 (ja) 2016-12-14 2022-10-28 パーデュー・リサーチ・ファウンデイション 線維芽細胞活性化タンパク質（ｆａｐ）標的イメージングおよび治療
WO2018129497A1 (en) 2017-01-09 2018-07-12 Bioxcel Therapeutics, Inc. Predictive and diagnostic methods for prostate cancer
WO2018187418A1 (en) * 2017-04-04 2018-10-11 Genentech, Inc. Substrates recognized by fibroblast activation protein (fap) and methods of using the same
GB201710973D0 (en) 2017-07-07 2017-08-23 Avacta Life Sciences Ltd Scaffold proteins
KR102005030B1 (ko) * 2017-10-31 2019-07-29 충북대학교 산학협력단 프로테아좀 억제제를 유효성분으로 포함하는 신경퇴행성 질환의 예방 또는 치료용 약학적 조성물
CN108191957B (zh) * 2017-12-30 2021-05-04 浙江大学 三肽大环衍生物及其制备方法和应用
JP2021512165A (ja) 2018-01-29 2021-05-13 コグノス・セラピューティクス・インコーポレイテッド ボルテゾミブの腫瘍内送達
PH12020551205A1 (en) * 2018-02-06 2021-04-19 Univ Heidelberg Fap inhibitors
US11466036B2 (en) * 2018-08-02 2022-10-11 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Borate of azetidine derivative
WO2020033437A1 (en) 2018-08-06 2020-02-13 University Of Kentucky Research Foundation Proteasome inhibitors
GB201820320D0 (en) * 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for FAPalpha
US20240092831A1 (en) * 2019-10-11 2024-03-21 Mayo Foundation For Medical Education And Research Proteasome Inhibitors
CN111235221B (zh) * 2020-01-22 2022-08-05 北京大学第一医院 一种fap抑制剂的活性检测方法
CZ309380B6 (cs) * 2020-03-30 2022-10-26 Ústav organické chemie a biochemie AV ČR v. v. i Sloučeniny pro inhibici fibroblastového aktivačního proteinu
EP4706662A1 (en) * 2020-06-17 2026-03-11 University of Utah Research Foundation Biomarker based patient selection for proteasome inhibitor treatment
UY39569A (es) 2020-12-17 2022-07-29 Astrazeneca Ab N-(2-(4-cianotiazolidin-3-il)-2-oxoetil)- quinolin-4-carboxamidas
EP4262878A1 (en) * 2020-12-17 2023-10-25 Trustees Of Tufts College Fap-activated radiotheranostics, and uses related thereto
JP2024510435A (ja) 2021-03-18 2024-03-07 シージェン インコーポレイテッド 生体活性化合物の内部移行複合体からの選択的薬物放出
US11806405B1 (en) 2021-07-19 2023-11-07 Zeno Management, Inc. Immunoconjugates and methods
CA3224492A1 (en) 2021-07-19 2023-01-26 Xiaojun Han Immunoconjugates and methods
TWI869142B (zh) * 2022-12-27 2025-01-01 大陸商上海美悦生物科技發展有限公司 三肽環氧酮化合物、藥物組合物及其製備方法和用途
US20250186630A1 (en) 2023-12-12 2025-06-12 Viewpoint Molecular Targeting, Inc. Fibroblast activation protein targeting peptides
WO2025159301A1 (ko) * 2024-01-24 2025-07-31 서울대학교산학협력단 섬유아세포 활성화 단백질에 의해 활성화되는 프로드러그 화합물
WO2025259682A1 (en) * 2024-06-10 2025-12-18 Trustees Of Tufts College Enzyme-activated prodrugs with small molecule-mediated extended serum half-life
WO2026060338A1 (en) * 2024-09-13 2026-03-19 Case Western Reserve University Anticancer mtor activator

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4499082A (en) 1983-12-05 1985-02-12 E. I. Du Pont De Nemours And Company α-Aminoboronic acid peptides
ZA86746B (en) 1985-02-04 1986-09-24 Merrell Dow Pharma Novel peptidase inhibitors
US4935493A (en) 1987-10-06 1990-06-19 E. I. Du Pont De Nemours And Company Protease inhibitors
US5462928A (en) 1990-04-14 1995-10-31 New England Medical Center Hospitals, Inc. Inhibitors of dipeptidyl-aminopeptidase type IV
US6825169B1 (en) 1991-10-22 2004-11-30 Trustees Of Tufts College Inhibitors of dipeptidyl-aminopeptidase type IV
DE69535019T2 (de) 1994-03-11 2007-01-04 Wilson Greatbatch, Ltd. Elektromagnetische pumpe mit geringem vermögen
US5580979A (en) 1994-03-15 1996-12-03 Trustees Of Tufts University Phosphotyrosine peptidomimetics for inhibiting SH2 domain interactions
US6083903A (en) * 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US6180402B1 (en) 1996-11-20 2001-01-30 Qlt Inc. Method for inhibiting apoptosis induced by photodynamic therapy using a cysteine or serine protease inhibitor
JP2001518290A (ja) 1997-09-29 2001-10-16 ポイント セラピューティクス， インコーポレイテッド インビトロでの造血細胞の刺激
EP1052994A2 (en) 1998-02-02 2000-11-22 Trustees Of Tufts College Use of dipeptidylpetidase inhibitors to regulate glucose metabolism
US6300314B1 (en) 1998-05-04 2001-10-09 Point Therapeutics, Inc. Hematopoietic stimulation
AU765370B2 (en) 1998-06-05 2003-09-18 Point Therapeutics, Inc. Cyclic boroproline compounds
US6979697B1 (en) 1998-08-21 2005-12-27 Point Therapeutics, Inc. Regulation of substrate activity
WO2000048302A1 (en) 1999-02-11 2000-08-17 Battelle Memorial Institute Power supply
US6890904B1 (en) 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
EP2769715A3 (en) 2001-11-26 2014-09-17 Trustees Of Tufts College Methods for treating autoimmune disorders, and reagents related thereto
JP4771661B2 (ja) 2001-11-26 2011-09-14 トラスティーズ オブ タフツ カレッジ Ｐｏｓｔ−プロリン開裂酵素の擬ペプチド性阻害剤
US7691967B2 (en) * 2002-04-30 2010-04-06 Trustees Of Tufts College Smart pro-drugs of serine protease inhibitors
WO2004004661A2 (en) 2002-07-09 2004-01-15 Point Therapeutics, Inc. Boroproline compound combination therapy
EP1633384B1 (en) 2003-05-15 2012-03-14 Trustees Of Tufts College Stable analogs of glp-1
AU2005216970B2 (en) 2004-02-23 2011-07-07 Trustees Of Tufts College Inhibitors of dipeptidylpeptidase IV for regulating glucose metabolism
US20060063719A1 (en) 2004-09-21 2006-03-23 Point Therapeutics, Inc. Methods for treating diabetes
CA2606785A1 (en) 2005-05-19 2006-11-23 Genentech, Inc. Fibroblast activation protein inhibitor compounds and methods
CN101247799B (zh) * 2005-07-05 2013-03-27 塔夫茨大学信托人 成纤维细胞活化蛋白α的抑制剂
AU2006201635A1 (en) * 2005-10-20 2007-05-10 Ludwig Institute For Cancer Research Novel inhibitors and methods for their preparation
CN101379069A (zh) * 2005-12-19 2009-03-04 塔夫茨大学信托人 软蛋白酶抑制剂及其前软形式
CA2656393A1 (en) * 2006-06-30 2008-01-10 Schering Corporation Method of using substituted piperidines that increase p53 activity
US20100184706A1 (en) * 2007-03-20 2010-07-22 Bachovchin William W Fap-activated chemotherapeutic compounds, and methods of use thereof
CA2681351A1 (en) 2007-03-20 2008-09-25 Trustees Of Tufts College Inhibitors of fibroblast activation protein, and methods of use thereof
WO2009006473A2 (en) * 2007-07-05 2009-01-08 Trustees Of Tufts College Pro-soft polypeptide proteasome inhibitors, and methods of use thereof
KR20140042933A (ko) * 2007-08-06 2014-04-07 밀레니엄 파머슈티컬스 인코퍼레이티드 프로테아좀 억제제
NZ600126A (en) * 2007-08-17 2013-12-20 Boehringer Ingelheim Int Purine derivatives for use in the treatment of fap-related diseases
AU2009221976B2 (en) * 2008-03-03 2014-02-27 Kansas State University Research Foundation Protease assay
JP5801585B2 (ja) 2011-03-30 2015-10-28 株式会社ケーヒン 燃料噴射制御システム
EP4706663A3 (en) 2011-08-30 2026-05-20 Trustees Of Tufts College FAP-ACTIVATED PROTEASOME INHIBITORS USED TO TREAT SOLID TUMORS

Also Published As

Publication number Publication date
EP4706663A3 (en) 2026-05-20
US20140255300A1 (en) 2014-09-11
US9956297B2 (en) 2018-05-01
EP4706663A2 (en) 2026-03-11
CN103945856A (zh) 2014-07-23
US20200323994A1 (en) 2020-10-15
EP4144354B1 (en) 2025-11-26
WO2013033396A2 (en) 2013-03-07
CA2846852C (en) 2021-01-12
HRP20221320T1 (hr) 2023-01-06
JP2014527070A (ja) 2014-10-09
US20250367304A1 (en) 2025-12-04
CA2846852A1 (en) 2013-03-07
SI2753334T1 (sl) 2023-01-31
PL2753334T3 (pl) 2022-12-12
EP2753334A2 (en) 2014-07-16
US9597410B2 (en) 2017-03-21
ES2929179T3 (es) 2022-11-25
US11065339B2 (en) 2021-07-20
EP4144354A1 (en) 2023-03-08
US12214047B2 (en) 2025-02-04
AU2012301810A1 (en) 2014-04-10
CN108383893A (zh) 2018-08-10
JP2018016629A (ja) 2018-02-01
WO2013033396A3 (en) 2014-05-08
AU2012301810B2 (en) 2017-06-01
PT2753334T (pt) 2022-11-03
US20160346401A1 (en) 2016-12-01
EP2753334A4 (en) 2015-07-01
EP2753334B1 (en) 2022-10-19
JP6207509B2 (ja) 2017-10-04
US10517955B2 (en) 2019-12-31
US20190054181A1 (en) 2019-02-21
AU2017204121A1 (en) 2017-07-06
HUE060305T2 (hu) 2023-02-28
US20210379190A1 (en) 2021-12-09

Similar Documents

Publication Publication Date Title
SI2753334T1 (sl) Fap-aktivirani proteasomski inhibitorji za zdravljenje solidnih tumorjev
DK3400944T3 (da) Ibat-inhibitorer til behandling af leversygdomme
DK3520805T3 (da) Sammensætninger til behandling af myelofibrose
EP2683693A4 (en) ROR-GAMMA-T INHIBITORS
SMT201700109B (it) Inibitori di istone demetilasi
HUE057264T2 (hu) Eljárás új IDH1 inhibitorok elõállítására
DK3628670T3 (da) Saltform til ezh2-hæmning
DK2558105T3 (da) Bardoxolonmethyl til behandling af fedme
PT2523661T (pt) Inibidores de nkcc para o tratamento de autismo
HUE040455T2 (hu) T-sejt aktiválás inhibitorai
EP2734529A4 (en) BTK INHIBITORS
HRP20180237T1 (hr) Metode za liječenje hcv-a
CO6930358A2 (es) Compuestos inhibidores de metaloenzimas
DK2785801T4 (da) Fremgangsmåde til formindskelse af isdannelse på et underlag
HRP20180809T1 (hr) Inhibicijski spojevi metaloenzima
EP2782570A4 (en) HETEROCYCLIC INHIBITORS OF GLUTAMINASE
DK2500036T3 (da) MET-hæmmere til øgning af virkningen af radioterapi
DK3412687T3 (da) Fremgangsmåder til behandling af dlbcl
DK2635282T3 (da) Sammensætninger til behandling af myelofibrose
BR112014002399A2 (pt) conjunto
DK3246042T3 (da) Lægemiddelresistent immunterapi til behandling af cancer
DK2662094T3 (da) Fremgangsmåder til cylodextrinkompleksdannelse til formulering af peptidproteasomhæmmere
IL226246A0 (en) Methods of treating cancer
EP2858975A4 (en) FBXO3 INHIBITORS
EP2629616A4 (en) SUBSTITUTED AMINO-TRIAZOLYL-PDE10-HEMMER